161 related articles for article (PubMed ID: 30694216)
21. Acarbose in the treatment of elderly patients with type 2 diabetes.
Josse RG; Chiasson JL; Ryan EA; Lau DC; Ross SA; Yale JF; Leiter LA; Maheux P; Tessier D; Wolever TM; Gerstein H; Rodger NW; Dornan JM; Murphy LJ; Rabasa-Lhoret R; Meneilly GS
Diabetes Res Clin Pract; 2003 Jan; 59(1):37-42. PubMed ID: 12482640
[TBL] [Abstract][Full Text] [Related]
22. [Already in altered glucose tolerance an antidiabetic drug. Significantly fewer heart attacks].
MMW Fortschr Med; 2003 Jan; 145(3-4):57. PubMed ID: 12619238
[No Abstract] [Full Text] [Related]
23. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
24. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes.
Joshi SR; Ramachandran A; Chadha M; Chatterjee S; Rathod R; Kalra S
Expert Opin Pharmacother; 2014 Aug; 15(11):1611-20. PubMed ID: 24963542
[TBL] [Abstract][Full Text] [Related]
25. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus.
Li C; Hung YJ; Qamruddin K; Aziz MF; Stein H; Schmidt B
Diabetes Res Clin Pract; 2011 Apr; 92(1):57-64. PubMed ID: 21251726
[TBL] [Abstract][Full Text] [Related]
26. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
Gu Y; Wang X; Li J; Zhang Y; Zhong H; Liu R; Zhang D; Feng Q; Xie X; Hong J; Ren H; Liu W; Ma J; Su Q; Zhang H; Yang J; Wang X; Zhao X; Gu W; Bi Y; Peng Y; Xu X; Xia H; Li F; Xu X; Yang H; Xu G; Madsen L; Kristiansen K; Ning G; Wang W
Nat Commun; 2017 Nov; 8(1):1785. PubMed ID: 29176714
[TBL] [Abstract][Full Text] [Related]
27. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
28. [Spectrum of apolipoproteins of blood serum in patients with non- insulin-dependent diabetes mellitus on acarbose treatment].
Rosliakova LV; Roĭtman AP; Rakov SS; Ametov AS; Dolgov VV
Klin Med (Mosk); 1999; 77(10):15-7. PubMed ID: 10635646
[No Abstract] [Full Text] [Related]
29. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
30. Acarbose: an alpha-glucosidase inhibitor.
Martin AE; Montgomery PA
Am J Health Syst Pharm; 1996 Oct; 53(19):2277-90; quiz 2336-7. PubMed ID: 8893066
[TBL] [Abstract][Full Text] [Related]
31. Acarbose: an alternative to metformin for first-line treatment in type 2 diabetes?
Ma RC
Lancet Diabetes Endocrinol; 2014 Jan; 2(1):6-7. PubMed ID: 24622656
[No Abstract] [Full Text] [Related]
32. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
33. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.
Rosenbaum P; Peres RB; Zanella MT; Ferreira SR
Braz J Med Biol Res; 2002 Aug; 35(8):877-84. PubMed ID: 12185379
[TBL] [Abstract][Full Text] [Related]
34. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
Hanefeld M; Schaper F
Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
[TBL] [Abstract][Full Text] [Related]
35. The changes of leukocyte telomere length and telomerase activity after sitagliptin intervention in newly diagnosed type 2 diabetes.
Ma D; Yu Y; Yu X; Zhang M; Yang Y
Diabetes Metab Res Rev; 2015 Mar; 31(3):256-61. PubMed ID: 25044768
[TBL] [Abstract][Full Text] [Related]
36. [Acarbose, an unduly neglected antidiabetic drug].
Iványi J; Gyimesi A
Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
[TBL] [Abstract][Full Text] [Related]
37. Acarbose vs metformin for new-onset type 2 diabetes.
Gallo M; Candido R; De Micheli A; Esposito K; Gentile S; Ceriello A;
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):104. PubMed ID: 24622707
[No Abstract] [Full Text] [Related]
38. Acarbose vs metformin for new-onset type 2 diabetes.
Tsujimoto T; Yamamoto-Honda R
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):104-5. PubMed ID: 24622706
[No Abstract] [Full Text] [Related]
39. Acarbose reduces the risk of pre-lunch hypoglycemia in elderly people with diabetes eating rice porridge for breakfast.
Hsieh CJ
Diabetes Res Clin Pract; 2010 Sep; 89(3):e66-8. PubMed ID: 20619914
[TBL] [Abstract][Full Text] [Related]
40. Epidemiological analysis of patients with Type 2 diabetes in France.
Grimaldi A; Grangé V; Allannic H; Passa P; Rodier M; Cornet P; Duprat I; Duc-Dodon P; Lemaire A; Liard F; Eschwège E
J Diabetes Complications; 2000; 14(5):242-9. PubMed ID: 11113685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
